Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

EDELMANN Jennifer MALČÍKOVÁ Jitka RICHES John C

Year of publication 2023
Type Article in Periodical
Magazine / Source Frontiers in Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full
Doi http://dx.doi.org/10.3389/fonc.2023.1106579
Keywords chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor
Attached files
Description The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.